PMV Pharmaceuticals insider tax-related share sale disclosed in Form 4

Q: What type of transaction did PMVP report on the Form 4?

The filing reports a sale (code “S”) of common stock by the CFO.

Q: How many PMVP shares were sold and at what price?

Michael Carulli sold 28,249 shares at a weighted-average price of $1.0647 .

Q: Why were the shares sold?

The shares were sold to cover tax obligations arising from the vesting of RSUs.

Q: How many shares does the CFO own after the transaction?

Following the sale, the CFO beneficially owns 60,146 PMVP shares .

Q: Were any derivative securities involved in this filing?

No, the filing shows no derivative security activity for the reported period.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

PMV Pharmaceuticals (PMVP) – Form 4 insider transaction

Chief Financial Officer Michael Carulli disclosed the sale of 28,249 common shares on 01 July 2025 at a weighted-average price of $1.0647 per share. According to the filing, the disposition was made solely to satisfy tax-withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, the executive continues to beneficially own 60,146 shares of PMVP common stock, and no derivative security activity was reported. The sale represents a cash value of roughly $30,000 and leaves the CFO with a meaningful equity stake, limiting the signaling impact for investors.

Positive

Sale attributed to tax-withholding, suggesting no discretionary reduction in exposure.
60,146 shares remain under the CFO’s direct ownership, maintaining alignment with shareholders.

Negative

Insider sale by a senior officer can be perceived as a modest negative signal despite its routine nature.

Insights

TL;DR: Routine tax-related sale; negligible governance signal.

The filing shows a standard RSU tax-withholding sale. Volume (28,249 shares) and value (~$30k) are immaterial versus typical insider trading thresholds, and the executive retains over 60k shares. Because the disposition is non-discretionary, it carries little informational content regarding the CFO’s outlook. I view the governance impact as neutral.

TL;DR: Small insider sale; limited market impact expected.

From a market perspective, the sale equals roughly one trading day’s volume for many micro-cap stocks and appears administrative. With no accompanying derivative transactions or changes in option holdings, the event does not alter the investment thesis. I classify the filing as not impactful for valuation or liquidity.

Insider Trade Summary

Net Seller: 28,249 shares ($30,077)

Net Sell 1 txn

Insider Carulli Michael

Role Chief Financial Officer

Sold 28,249 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock	28,249	$1.0647	$30K

Holdings After Transaction: Common Stock — 60,146 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

07/03/2025 - 07:49 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carulli Michael

(Last)

(First)

(Middle)

C/O PMV PHARMACEUTICALS, INC.

ONE RESEARCH WAY

(Street)

PRINCETON

08540

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2025		S		28,249⁽¹⁾	D	$1.0647	60,146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

	/s/ Robert Ticktin, by power of attorney	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What type of transaction did PMVP report on the Form 4?

The filing reports a sale (code “S”) of common stock by the CFO.

How many PMVP shares were sold and at what price?

Michael Carulli sold 28,249 shares at a weighted-average price of $1.0647.

Why were the shares sold?

The shares were sold to cover tax obligations arising from the vesting of RSUs.

How many shares does the CFO own after the transaction?

Following the sale, the CFO beneficially owns 60,146 PMVP shares.

Were any derivative securities involved in this filing?

No, the filing shows no derivative security activity for the reported period.